Search This Blog

Friday, August 2, 2019

Momenta misses Q3 consensus

Momenta Pharmaceuticals (MNTA) Q3 results: Revenues: $5.2M (-60.0%); Product revenue: $3.3M (-72.0%); R&D revenue: $1.8M (+38.5%).
Net Loss: ($114M) (-62.9%); Loss Per Share: ($1.16) (-27.5%); Quick Assets: $344.1M (-23.4%).
The Company launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), with top-line data expected by end of 2021.
Momenta also received FDA Fast Track Designation for nipocalimab in wAIHA and hemolytic disease of the fetus and newborn.
Momenta Pharmaceuticals (MNTA) Q3 results: Revenues: $5.2M (-60.0%); Product revenue: $3.3M (-72.0%); R&D revenue: $1.8M (+38.5%).
Net Loss: ($114M) (-62.9%); Loss Per Share: ($1.16) (-27.5%); Quick Assets: $344.1M (-23.4%).
The Company launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), with top-line data expected by end of 2021.
Momenta also received FDA Fast Track Designation for nipocalimab in wAIHA and hemolytic disease of the fetus and newborn.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.